Histogen to Report First Quarter 2022 Financial Results and Provide Business Update
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, will release its financial results for Q1 2022 after market close on May 12, 2022. The company focuses on restorative therapeutics and caspase inhibitors for infectious and inflammatory diseases. Key product candidates include HST-003 for joint cartilage repair and HST-004 for spinal disc repair. Notably, emricasan is being developed for COVID-19 treatment in partnership with Amerimmune and is under evaluation for other diseases like MRSA.
- Emricasan, a key candidate, is being developed for COVID-19 treatment.
- The company has a diverse pipeline including HST-003 and HST-004 for joint and spinal repairs.
- None.
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing both potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function as well as a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases. Under our biologics technology platform, our product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. In addition, within our small molecule pipeline, our product candidates include emricasan, CTS-2090 and CTS-2096. Currently, emricasan is being developed jointly with our collaboration partner, Amerimmune, for the treatment of COVID-19, and we are evaluating the use of emricasan for other infectious diseases including the treatment of MRSA. We also have preclinical product candidates, CTS-2090 and CTS-2096, novel, potent, orally bioavailable, and highly selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
When will Histogen Inc. announce its Q1 2022 financial results?
What are the key products being developed by Histogen Inc.?
What is the stock symbol for Histogen Inc.?
